Imibuzo Ephathelene Nezidakamizwa Ze-Arthritis Rheumatoid
I-TNF inhibitors imithi yokwelapha i-rheumatoid arthritis. Njengazo zonke izidakamizwa, zingasebenza kakhulu kubantu abathile futhi ngaphansi kwabanye. Nakhu ukubuka ukuthi yini i-TNF inhibitors kanye nokuthi isebenza kanjani, yiziphi imiphumela emibi engaba nayo, nokuthi yiziphi eziqhathaniswayo eziqhathaniswayo.
Yini i-TNF inhibitors?
I-TNF inhibitors yinkimbinkimbi, izidakamizwa ezinzima ezikhona ekilasini lemithi ebizwa nge-biologics.
Basebenza ngokukhomba into ebizwa ngokuthi i-tumor necrosis factor eyenza ukuvuvukala. Ezinye zezinto eziphilayo zokwelapha i-rheumatoid arthritis ziyi-antibodies e-monoclonal.
I-Biologics yizidakamizwa ezikhomba amamolekhi abangela ukuvuvukala nokulimala amalunga. Zivame ukubekwa kubantu abathatha ezinye izinhlobo zemithi ye-arthritis, njenge-DMARD (isifo sokuguqula izidakamizwa eziphikisayo), kodwa hhayi ukuthola ukukhululeka okwanele.
I-Tumor Necrosis Factor yiprotheni eyenziwa yisistimu yomzimba. Idlala indima emisebenzini eminingi ebalulekile yomzimba, njenge-fat metabolism kanye ne-coagulation, noma i-clotting, yamaseli egazi. Izimo ezithile, kuhlanganise nomdlavuza nezifo ezizimele njenge-rheumatoid arthritis, zingabangela ukwedlula ngokweqile kwe-TNF, okuholela ekuvukeleni.
Uyazi kakade ukuthi ama-antibodies ayizinto ezikhiqizwa amasosha omzimba ukulwa nama-antigen njengama-virus.
Ama-antibodies a-monoclonal akhiqizwa ebhodini futhi ahloselwe ukukhomba ama-molecule athile, afana ne-TNF.
Ukuqhathanisa i-TNF Inhibitors
Kuhlale kubalulekile ukubuka ukufana nokuhlukana phakathi kwemithi uma wena nodokotela wakho nithatha ukwelashwa okulungile kuwe. Ezinye izici okufanele zicatshangelwe uma ukhetha phakathi kwezivimbela ze-TNF zindlela ngamunye anikezwa ngayo, imiphumela emibi, kanye nezindleko.
I-Enbrel (etanercept) yayiyisilonda sokuqala se-anti-TNF. Kwamukelwa yi-US Food and Drug Administration (FDA) ngonyaka ka-1998. Isibungu sitholwa ngokufaka i-DNA yabantu kumaseli ase-Chinese hamster ovary ukudala amaprotheni akhiqiza izakhi.
I-Remicade (i-infliximab) i-antibody yamonoclonal ehlanganisa futhi igweme i-necrosis factor alpha (TNF-alpha). Kwakuyi-TNF yesibili inhibitor ukuba i-FDA ivunyiwe, ngo-1999.
U-Humira (adalimumab) "u-antibody ophelele" owenziwe nge-humoconal "ngokugcwele, okusho ukuthi ukwakheka kwesidakamizwa kufana nalokho okwenziwe ngama-antibodies omuntu, noma ngabe wadalwa ebhodini. UHumira wamukelwa yi-FDA ngo-2002.
Cimzia
I-Cimzia (certolizumab pegol) yiyona kuphela i-TNF inhibitor ethinta ukuthi ingaphansi kobuhlungu kumaseli ngenxa yamakhemikhali ayo. Ngaphezu kwalokho, uma kuqhathaniswa nezinye izidakamizwa ezilwa ne-TNF, kubikwa ukuthi i-Cimzia inezinhlobo eziphakeme ze-TNF yabantu.
Simponi
I-Simponi (i-golimumab) i-blocker ye-TNF-alpha enqunyelwe ukuba i-ulcerative colitis, i-psoriatic arthritis, kanye ne-ankylosing spondylitis. Kwavunyelwa ngo-2004.
Imiphumela emibi ye-Blockers ye-TNF
Ayikho imithi engenamiphumela emibi. Izinkinga ezithile ezingase zihlotshaniswe nama-block block TNF aziwa kahle, okwenza ezinye iziguli ze-arthritis ziqaphe ngokuthatha ama-inhibitors we-TNF .
Kodwa kubantu abaningi, izinzuzo zidlula kakhulu izingozi.
Ezinye iziguli zijwayele ukutheleleka ngenkathi ziphathwa nge-DMARD noma izidakamizwa ze-biologic. (Kunjalo nakwa-DMARD.)
Ucwaningo lwango-2016 lwathola ukuthi abantu abathinte izifo ezithile ze-TNF zesifo samathambo esifubeni babenengozi yokuthuthukisa ezinye zegciwane, njenge-lymphoma. Lokhu kwakuyiqiniso ikakhulukazi uma bephezulu kakhulu.
Funda mayelana nakho
I-arthritis ngaphandle kobuhlungu - Isimangaliso se-TNF Blockers
Le ncwadi yi-rheumatologist uScott J. Zashin, MD, ichaza indlela abasebenzi be-TNF basebenza ngayo nokuthi baqhathanisa kanjani nezinye izidakamizwa zamagciwane.
Uhlanganisa izindaba zokuphumelela ngesineke futhi ungena kanjani ukuthi leli klasi lokuphumelela kwezidakamizwa lishintshile impilo.